High-Risk Percutaneous Intervention in the Drug-Eluting Stent Era
(Risicovolle percutane interventies in het drug-eluting stent tijdperk)
View PDF Version
High-risk Intervention in the Drug-eluting stent era The use of drug-eluting stents in high-risk interventions, including those undertaken to treat the left main coronary artery (Chapter 2), multivessel disease (Chapter 14) or on-going ST-segment elevation myocardial infarction (Chapters 11 and 12) appeared overall beneficial in comparison with traditional metallic stents. In particular, the use of drug eluting stents was associated to a remarkable decrease in late loss (Chapter 3) which ultimately resulted in lower need for re- intervention (Chapter 2), while no clear effect on death and myocardial infarction was observed. The safety profile of these new coronary devices appeared overall consistent with what has been reported in the pivotal trials focusing on selected patient/lesion subsets (Chapters 2, 3, 7, 8, 12, 14, 15, 16). The incidence of possible or confirmed acute, sub-acute or late thrombosis was low in this high-risk subset of patients patients undergoing treatment for left main coronary artery disease (Chapters 2, 3, 7, 8, 12, 14, 15, 16) and importantly we could not confirm previous concerns regarding the potential association between intimal hyperplasia and sudden death in patients undergoing treatment for left main coronary artery disease (Chapters 7 and 8).
The Netherlands Heart Foundation
Feyter, Prof. Dr. P.J. de
Serruys, Prof. Dr. P.W.J.C.